Literature DB >> 7390968

Mechanism of the inhibition of calf thymus DNA polymerases alpha and beta by daunomycin and adriamycin.

M Tanaka, S Yoshida.   

Abstract

The anthracycline antibiotics, daunomycin and adriamycin, strongly inhibited the reactions of both DNA polymerase alpha and beta from calf thymus by competing with the template primers, i.e., activated DNA or initiated deoxyhomopolymers. DNA polymerase alpha was more sensitive to both drugs than DNA polymerase beta with all the template-primers tested. With poly(dT).oligo(dA), the activity of the alpha-enzyme was extremely sensitive to these drugs (Ki, 0.9 microM for daunomycin), while that of the beta-enzyme was relatively resistant (Ki, 25 microM for daunomycin). Much stronger inhibition was produced by preincubating these drugs with the enzymes than with the template-primers, and the inhibition of DNA polymerase activity was reversed by the addition of excess template-primers. These results indicate that the inhibition was produced mainly by direct interaction of the drugs with DNA polymerases rather than by impairing the template activity of DNA due to intercalation of the drugs. Although adriamycin inhibited DNA polymerases alpha and beta to slightly higher extents than daunomycin, the modes of inhibition by these two drugs were quite similar.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 7390968     DOI: 10.1093/oxfordjournals.jbchem.a132821

Source DB:  PubMed          Journal:  J Biochem        ISSN: 0021-924X            Impact factor:   3.387


  8 in total

1.  Preferential inhibition of DNA polymerases alpha, delta, and epsilon from Novikoff hepatoma cells by inhibitors of cell proliferation.

Authors:  G Fox; O Popanda; L Edler; H W Thielmann
Journal:  J Cancer Res Clin Oncol       Date:  1996       Impact factor: 4.553

Review 2.  Clinical pharmacokinetics of doxorubicin.

Authors:  P A Speth; Q G van Hoesel; C Haanen
Journal:  Clin Pharmacokinet       Date:  1988-07       Impact factor: 6.447

3.  Interaction between second generation anthracyclines and DNA in the nucleosomal structure.

Authors:  C Cera; G Palù; S M Magno; M Palumbo
Journal:  Nucleic Acids Res       Date:  1991-05-11       Impact factor: 16.971

Review 4.  Epirubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in cancer chemotherapy.

Authors:  G L Plosker; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

5.  Cognitive dysfunction induced by chronic administration of common cancer chemotherapeutics in rats.

Authors:  Gregory W Konat; Michal Kraszpulski; Isaac James; Han-Ting Zhang; Jame Abraham
Journal:  Metab Brain Dis       Date:  2008-08-09       Impact factor: 3.584

6.  Mechanism of action of cinodine, a glycocinnamoylspermidine antibiotic.

Authors:  M Greenstein; J L Speth; W M Maiese
Journal:  Antimicrob Agents Chemother       Date:  1981-10       Impact factor: 5.191

7.  The peculiar binding properties of 4'-deoxy,4'-iododoxorubicin to isolated DNA and 175 bp nucleosomes.

Authors:  C Cera; M Palumbo
Journal:  Nucleic Acids Res       Date:  1991-10-25       Impact factor: 16.971

8.  Doxorubicin-induced elevated oxidative stress and neurochemical alterations in brain and cognitive decline: protection by MESNA and insights into mechanisms of chemotherapy-induced cognitive impairment ("chemobrain").

Authors:  Jeriel T R Keeney; Xiaojia Ren; Govind Warrier; Teresa Noel; David K Powell; Jennifer M Brelsfoard; Rukhsana Sultana; Kathryn E Saatman; Daret K St Clair; D Allan Butterfield
Journal:  Oncotarget       Date:  2018-07-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.